INTRODUCTION {#sec1-1}
============

Muscle cramps are painful, local, tangible, and involuntary skeletal muscular contractions that usually affect leg muscles.\[[@ref1]\] Muscle cramps are one of the common symptoms of pregnancy, especially during the third trimester\[[@ref2]\] that are often unidirectional.\[[@ref2]\] Leg cramps mostly happen twice a week or less frequently,\[[@ref3]\] usually at night,\[[@ref1][@ref3]\] last a few seconds to a few minutes, and mostly disappear by themselves.\[[@ref1]\]

Leg cramps occur in about 50% of pregnant women\[[@ref3][@ref4]\] and subside after delivery.\[[@ref2]\] The mechanism for cramping is not known yet and is likely to be idiopathic, but it could be due to physiological changes in neuromuscular performance, weight gain, joint laxity in the final stages of pregnancy, impaired blood supply to lower body organs, and increased pressure on leg muscles during pregnancy.\[[@ref2][@ref4]\] Pressure on blood vessels and nerves resulting from the enlarged uterus, imbalances between the intake and output of electrolytes and vitamins, and insufficient minerals intake might be other reasons for cramping. Hence, could increase glomerular filtration and greater needs of the fetus for receiving minerals from the mother (which reduces her serum calcium and magnesium levels).\[[@ref2][@ref5][@ref6][@ref7][@ref8]\]

Cramps during pregnancy are not related to pregnancy complications and are not accompanied by undesirable consequences for the fetus,\[[@ref9]\] but the American Sleep Association considers leg cramps as one of the reasons for sleep disorders during pregnancy.\[[@ref10]\] Sleep disorder resulting from cramps influences performance of daily activities and may lengthen the duration of pregnancy and the type of childbirth.\[[@ref5][@ref11]\] Moreover, the findings of studies have suggested that women with snoring in pregnancy have a higher risk for growth retardation of the fetus;\[[@ref12][@ref13]\] and women with sleep deprivation have a higher risk for preterm births.\[[@ref5]\]

Various treatments have been suggested for preventing and curing leg cramps during pregnancy including taking Vitamins B1, B6,\[[@ref14]\] E,\[[@ref15]\] and C\[[@ref16]\] and magnesium.\[[@ref17]\] The effects of the calcium supplement on improving leg cramps during pregnancy were investigated in many studies. Some of these studies reported relative or complete improvements of symptoms when calcium supplements were taken\[[@ref15][@ref16][@ref18]\] while others stated these supplements were ineffective.\[[@ref17]\]

Vitamin D is a fat-soluble vitamin found in very small quantities in natural food materials. Increased serum calcium improves metabolic and neuromuscular performance and bone health.\[[@ref19]\] Taking calcium supplement in food materials is necessary during pregnancy to prevent depletion of calcium in the mother\'s body.\[[@ref20]\] Furthermore, Vitamin D supplement\[[@ref21]\] during pregnancy is necessary.

Leg cramps are very prevalent in pregnant women and have negative influences on pregnant women\'s sleep performance and quality. Moreover, the mechanism of the effects of Vitamin D on calcium is not known and no study has been conducted on the effects of Vitamin D on leg cramps. Furthermore, Vitamin D is present in very quantities in food materials, vitamins are cheap, and pregnant women are very willing to take vitamins. That is why we decided to conduct a study on the therapeutic effects of Vitamin D and calcium plus Vitamin D supplement on leg cramps during pregnancy.

MATERIALS AND METHODS {#sec1-2}
=====================

Study design and participants {#sec2-1}
-----------------------------

This study was conducted as a double-blind randomized controlled clinical trial on pregnant women who were referred to health-care centers in Tabriz-Iran, 2013.

### Inclusion criteria included {#sec3-1}

A 18--35-year-old, being in 25^th^--30^th^ week of pregnancy and having minimum of two cramps during the week. Exclusion criteria included history of chronic diseases, kidney problems, osteomalacia, active thyroid or parathyroid diseases, endocrine disorders, hypertension, use of diuretics, calcium-blockers intake, chronic hypertension, and history of allergy to the study supplements.

Considering research carried out by Yaghmaei *et al*.\[[@ref22]\] and since α =0.05, β =0.02, m~1~ =49.17 (the overall mean score of cramp intensity before prevention), m~2~ =35 (the overall mean score of cramp intensity after the intervention), Sd~1~ =20.6, and Sd~2~ =23, the calculated number of participants for each group was 38. However, 42 participants were placed in each group to allow for dropouts.

Data collection tool {#sec2-2}
--------------------

The tools used for collecting data included sociodemographic and midwifery questionnaires and checklists to record weekly information on leg cramps in the 3^rd^ and 6^th^ week of the intervention. The participants marked information on the frequency, intensity (in the Visual Analog Scale \[VAS\], graded from 0 to 10 with zero for lack of pain and ten for very severe pain, for each cramping event), length (in minutes), and the time leg cramps happened in the checklists during the 3^rd^ and 6^th^ week of the intervention. At the end of the 3^rd^ and 6^th^ week of the intervention, the participants marked the checklist table related to side effects of taking the Vitamin D and Vitamin D plus calcium supplements. Furthermore, to control for the potentially confounding factor of diet, a dietary record questionnaire including foods containing calcium and Vitamin D was also completed by the participants during 1 week before intervention.

Sociodemographic and midwifery questionnaire as well as checklists for recording number and length of leg cramps were designed by research team and the content and face validity of them were confirmed by ten faculty members of Tabriz University of Medical Sciences. The VAS is a standard scale\[[@ref23]\] and used in several studies in Iran.\[[@ref24][@ref25]\]

Sampling {#sec2-3}
--------

Sampling started after obtaining ethical code from the ethics committee of research and technology deputy of Tabriz University of Medical Sciences under the number 91230 and registering the trial in the IRCT website under the code IRCT2013040810324N12. Thirty-three health centers from various areas in Tabriz, with different sociocultural situations that were visited by the largest numbers of women were first selected from the total of eighty health centers in the city. Health centers in the country are public, nonreferral, and governmental that all primary care services, including prenatal care, are provided free of charge. The participants were selected by purposefully method sampling. A list of all pregnant women in their 25^th^--30^th^ week of pregnancy who visited the selected centers was prepared. They were then contacted by telephone and invited to take part in the study. During their first visit to the center, the goals and method of the study were explained and the checklists for recording characteristics of leg cramps including the frequency, length, and intensity of leg cramps were given to them to record these during the week before the intervention started. At the end of this week, those who had recorded two and more cramps during the week and had other eligibility criteria entered the study and completed their informed written consent to participate in the research.

Randomization {#sec2-4}
-------------

The participants were allocated to three groups using a randomized block design with block sizes of three and six with the allocation ratio 1:1:1. To hide the allocation, each participant received two small envelopes, each with enough medicine for 3 weeks, inside a large matte-colored envelope of the same shape that were serially numbered. Each participant received one pill every day for 42 days.

Intervention {#sec2-5}
------------

Pills containing Vitamin D (1000 units) or Vitamin D plus calcium complements (300 mg of calcium carbonate and 1000 units of Vitamin D) were of the same shape, size, and weight as the placebo pills. The pills were prepared by the Faculty of Pharmacy in Tabriz University of Medical Sciences, Iran.

At the start of the intervention, each participant received a small envelope containing calcium plus Vitamin D or Vitamin D or the placebo, a checklist for recording leg cramp characteristics, and a checklist for recording daily multivitamins and pills taken during 3 weeks. They were asked to mark the checklists every time they took the pills. At the end of the 2^nd^ week of the study, the participants were called and asked to record the characteristics of leg cramps during the third week in the related checklists. They were reminded to bring the medicine envelope and the checklist for leg cramps during the 3^rd^ week and the checklist of medicines taken with them at the next follow-up that was at the end of the 3^rd^ week. During this visit, each of the participants received a second envelope with the same content as the first, together with the checklists for the second 3-week period. At the end of the 5^th^ week, the participants were called and reminded to record the characteristics of the leg cramps that happened during the 6^th^ week in the related checklists. They were asked to bring these checklists and the checklists related to the medicines taken, together with the second envelopes, with them to the second follow-up visit at the end of the 6^th^ week.

Data analysis {#sec2-6}
-------------

The data were analyzed using SPSS/version 13 (SPSS Inc., Chicago). The K-S test was used to investigate the normality of the quantitative data. The variables of the length of cramps before the intervention, during the 3^rd^ week of the intervention, and during the 6^th^ week of the intervention were not normal. The variable of the number of cramps was considered as discrete variable. The Chi-square, Chi-square for trend, Fisher exact test, and one-way ANOVA were used to examine the consistency of study groups. To compare the average pain severity of leg cramps between three groups, repeated measures ANOVA was used after intervention with adjusting for basic score. The baseline (preintervention) value of pain severity as possible confounder factor was entered to repeated measures ANOVA model as covariate. Sidak test was used as *post hoc* test for pairwise comparisons. Kruskal--Wallis and Friedman tests were used, respectively, for inter- and intra-groups comparisons of the number and the length of leg cramps before, during the 3^rd^, and 6^th^ after the start of the intervention. The power of repeated measures ANOVA test was equal with 0.74.

RESULTS {#sec1-3}
=======

In this study, 126 pregnant women with leg cramps from July 2013 to January 2014 entered the study and their conditions were followed up to April 2014. The flowchart of this study was indicated in [Figure 1](#F1){ref-type="fig"}.

![Flowchart of the study](JRMS-22-24-g001){#F1}

There were no statistical differences between groups regarding consuming of foods containing calcium and Vitamin D during 1 week before intervention (*P* = 0.204) and sociodemographic characteristics (*P* \> 0.05) except of prepregnancy body mass index (BMI) (*P* = 0.024) and BMI during pregnancy (*P* = 0.008) \[[Table 1](#T1){ref-type="table"}\].

###### 

Demographic and obstetrical characteristics of the participants by study groups

![](JRMS-22-24-g002)

Before the intervention, there was no statistically significant difference between the groups in terms of length (*P* = 0.160) and pain severity of leg cramps (*P* = 0.990), but there was statistically significant difference between the groups in terms of weekly number of leg cramps (*P* = 0.012) \[Tables [2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}\].

###### 

Comparison of the leg cramps number in pregnancy in three groups of study

![](JRMS-22-24-g003)

###### 

Comparison of the leg cramps length (min) in pregnancy in three groups of study

![](JRMS-22-24-g004)

###### 

Comparison of the severity of leg cramps pain (Visual Analog Scale) in pregnancy in three groups of study

![](JRMS-22-24-g005)

According to Kruskal--Wallis test, there was significant difference between the groups in terms of the weekly number of leg cramp during the 3^rd^ week after the start of the intervention (*P* = 0.033) and the number of leg cramp was less in the control group. However, there was no significant difference between the groups during 6^th^ week after the start of the intervention (*P* = 0.098) \[[Table 2](#T2){ref-type="table"}\]. Furthermore, there was no significant difference between the groups in terms of the length of leg cramps during the 3^rd^ week (*P* = 0.308) and 6^th^ week after the start of the intervention (*P* = 0.079) \[[Table 3](#T3){ref-type="table"}\]. In addition, the weekly number of leg cramp and the length of leg cramps were significantly decreased in each three groups according based on intra-groups comparison by Friedman test (*P* \< 0.05) \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].

Based on the repeated measure ANOVA test with adjusting for baseline value, there was no statistically significant difference between the Vitamin D and control groups (*P* = 0.814), calcium-Vitamin D and control groups (*P* = 0.931), and also between two treatment groups (*P* = 0.993) \[[Table 4](#T4){ref-type="table"}\].

At the end of the 6 weeks, two participants in the group receiving calcium-Vitamin D, 13 in the group receiving Vitamin D, and six in the group receiving placebo reported itching. Furthermore, six participants in the group receiving calcium-Vitamin D, 14 in the group receiving Vitamin D, and six in the group receiving placebo reported they experienced dry mouth.

DISCUSSION {#sec1-4}
==========

Results of this research showed that the calcium-Vitamin D and Vitamin D supplements had no effect on the number, length, and pain severity in leg cramps during the 6 weeks of the study.

Danesh Shahrakiconducted a study on three groups of pregnant women with leg cramps (who received calcium, Vitamin E, or magnesium milk) with no control group. They found that prescribing calcium carbonate at 500 mg/day for 45 days reduced the number, length, and pain intensity on the 45^th^ day, but that on the 90^th^ day after the first visit, these figures returned to their previous values.\[[@ref15]\] Their results are not consistent with those of the present study.

Khoramroudi *et al*. observed that prescription of calcium at 500 mg/day for 40 days reduced the number of leg cramps but had no effect on pain intensity.\[[@ref25]\] Moreover, according to the study of Hammar *et al*. (1987), prescription of one gram of calcium for 2 weeks clinically improved leg cramps.\[[@ref18]\] Results of these two studies do not conform to those found in the present study, probably due to the difference in the doses of the prescribed medicines, and because calcium was used together with Vitamin D in our research. We suggest that future studies be carried out using higher doses to determine the effective one.

According to the study by Zhou *et al*., there was no difference in the frequency of leg cramps after treatment with calcium versus Vitamin C.\[[@ref16]\] Since the control group received ascorbic acid in their study, and cramps improved relatively or completely in most participants. Thus, ascorbic acid may also be effective in treating muscle cramps.

The results of systematic review by Young *et al*. showed that calcium can decrease pain in a leg cramps and it has positive effect on treatment.\[[@ref17]\] Furthermore, the results of Cochrane systematic review showed that a greater proportion of women receiving calcium supplements experienced no leg cramps after treatment than those receiving no treatment. This review suggested that large well-conducted randomized controlled trials are needed in this regard due to poor study design and small sample size of trials. The results of these reviews are not consistent with those of present study.

The above-mentioned studies have assessed the effects of calcium on leg cramps but no studies have been conducted so far on the effect of Vitamin D supplement on cramps. However, calcium and bone metabolisms greatly depend on Vitamin D concentration and on its metabolically active form, 1,25(OH)2D, and the human body cannot absorb sufficient Ca and *P* without the help of 1,25(OH)2D.\[[@ref26]\] Moreover, the 1,25(OH)2D produced in the kidneys stimulate the calcium reserve in bone tissues and in the intestines and helps Ca and *P* absorption; and finally, the combination of these activities increases serum Ca and P. Increased levels of serum Ca and *P* cause improvements in metabolic performances, bone health, and neuromuscular functions.\[[@ref19]\] As Vitamin D and Ca had no effect on leg cramps in our study, and because the main reason for, and the mechanism of leg cramps in pregnancy are not clear yet,\[[@ref2]\] leg cramps during pregnancy may not be due to calcium deficiency and could have other causes.

Lack of visual observation to investigate pain intensity in leg cramps was one of the limitations of this study. Furthermore, the impossibility of measuring blood calcium and Vitamin D levels was another limitation. It is recommended that future clinical trials should investigate the effects of Vitamin D and calcium-Vitamin D supplements with different doses of these materials, intervention should take place using a larger sample, and serum calcium and Vitamin D levels ought to be assessed to obtain results that are more accurate.

CONCLUSION {#sec1-5}
==========

Results of this study indicated that taking 1000 IU Vitamin D and 300 mg calcium plus 1000 IU Vitamin D every day for 6 weeks has no effect on leg cramps. One of the limitations in this study was the short follow-up period, so that a follow-up period longer than 6 weeks in the future researches was suggested. Furthermore, the serum levels of calcium and Vitamin D did not determined in this study due to cost restrictions. Therefore, these supplements should be administrated by assessing their serum levels before and after the intervention.
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